e 4031 has been researched along with Long QT Syndrome in 47 studies
E 4031: class III anti-arrhythmia agent; structure given in UD
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the cellular and ionic mechanism for QT prolongation and subsequent Torsade de Pointes (TdP) and the effect of verapamil under conditions mimicking KCNQ1 (I(Ks) gene) defect linked to acquired long QT syndrome (LQTS)." | 7.73 | Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. ( Aiba, T; Ding, WG; Horie, M; Inagaki, M; Matsuura, H; Miyoshi, S; Noda, T; Shimizu, W; Sunagawa, K; Toyoda, F; Zankov, DP, 2005) |
| "Droperidol is a highly potent butyrophenone used for the therapy of postoperative nausea and vomiting." | 5.36 | The subtype-specific effects of droperidol on action potential duration in cellular and computational models of long QT syndrome. ( Ehmke, H; Friederich, P; Kebernik, J; Schwoerer, AP, 2010) |
| "Fluoxetine (Prozac) is a widely prescribed drug in adults and children, and it has an active metabolite, norfluoxetine, with a prolonged elimination time." | 5.33 | Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. ( Anderson, CL; Anson, BD; Delisle, BP; Eckhardt, LL; Gillman, BM; Holzem, KM; January, CT; Klemens, CA; Makielski, JC; Rajamani, S; Valdivia, CR, 2006) |
| " Phenylephrine-induced reflex bradycardia increased QTbtb by 3 ms but decreased QTcB by 20 ms and QTcF by 12 ms." | 3.73 | Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. ( Crimin, K; Fossa, AA; Gorczyca, W; Magnano, A; Raunig, DL; Winslow, R; Wisialowski, T; Wolfgang, E, 2005) |
| "We examined the cellular and ionic mechanism for QT prolongation and subsequent Torsade de Pointes (TdP) and the effect of verapamil under conditions mimicking KCNQ1 (I(Ks) gene) defect linked to acquired long QT syndrome (LQTS)." | 3.73 | Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. ( Aiba, T; Ding, WG; Horie, M; Inagaki, M; Matsuura, H; Miyoshi, S; Noda, T; Shimizu, W; Sunagawa, K; Toyoda, F; Zankov, DP, 2005) |
| "Fluoxetine (Prozac) was more potent at blocking hERG 1a/1b than 1a channels, yielding a corresponding reduction in the safety margin." | 1.37 | hERG subunit composition determines differential drug sensitivity. ( Abi-Gerges, N; Holkham, H; Jones, EM; Pollard, CE; Robertson, GA; Valentin, JP, 2011) |
| "Droperidol is a highly potent butyrophenone used for the therapy of postoperative nausea and vomiting." | 1.36 | The subtype-specific effects of droperidol on action potential duration in cellular and computational models of long QT syndrome. ( Ehmke, H; Friederich, P; Kebernik, J; Schwoerer, AP, 2010) |
| "The long QT syndrome is characterized by a prolongation of the QT interval measured on the surface electrocardiogram." | 1.35 | In vivo effects of the IKr agonist NS3623 on cardiac electrophysiology of the guinea pig. ( Grunnet, M; Hansen, RS; Olesen, SP; Rønn, LC, 2008) |
| "Fluoxetine (Prozac) is a widely prescribed drug in adults and children, and it has an active metabolite, norfluoxetine, with a prolonged elimination time." | 1.33 | Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. ( Anderson, CL; Anson, BD; Delisle, BP; Eckhardt, LL; Gillman, BM; Holzem, KM; January, CT; Klemens, CA; Makielski, JC; Rajamani, S; Valdivia, CR, 2006) |
| "Nisoldipine (1 microM) was used to block inward calcium current (I(Ca)) and E-4031 (1-5 microM) was applied to inhibit the rapid component of the delayed rectifier potassium current (I(Kr))." | 1.31 | The slow component of the delayed rectifier potassium current in undiseased human ventricular myocytes. ( Bogáts, G; Iost, N; Opincariu, M; Papp, JG; Szécsi, J; Szenohradszky, P; Szolnoky, J; Varró, A; Virág, L, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (8.51) | 18.2507 |
| 2000's | 28 (59.57) | 29.6817 |
| 2010's | 12 (25.53) | 24.3611 |
| 2020's | 3 (6.38) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, W | 1 |
| Wymore, RS | 1 |
| Wang, HS | 1 |
| Pan, Z | 1 |
| Cohen, IS | 1 |
| McKinnon, D | 1 |
| Dixon, JE | 1 |
| Cavalli, A | 1 |
| Poluzzi, E | 1 |
| De Ponti, F | 1 |
| Recanatini, M | 1 |
| He, S | 1 |
| Moutaoufik, MT | 1 |
| Islam, S | 1 |
| Persad, A | 1 |
| Wu, A | 1 |
| Aly, KA | 1 |
| Fonge, H | 1 |
| Babu, M | 1 |
| Cayabyab, FS | 1 |
| De Waard, S | 1 |
| Montnach, J | 1 |
| Ribeiro, B | 1 |
| Nicolas, S | 1 |
| Forest, V | 1 |
| Charpentier, F | 2 |
| Mangoni, ME | 1 |
| Gaborit, N | 1 |
| Ronjat, M | 1 |
| Loussouarn, G | 1 |
| Lemarchand, P | 1 |
| De Waard, M | 1 |
| Brandão, KO | 1 |
| van den Brink, L | 1 |
| Miller, DC | 1 |
| Grandela, C | 1 |
| van Meer, BJ | 1 |
| Mol, MPH | 1 |
| de Korte, T | 1 |
| Tertoolen, LGJ | 1 |
| Mummery, CL | 1 |
| Sala, L | 1 |
| Verkerk, AO | 1 |
| Davis, RP | 1 |
| Fukumoto, D | 1 |
| Ding, WG | 2 |
| Wada, Y | 1 |
| Fujii, Y | 1 |
| Ichikawa, M | 1 |
| Takayama, K | 1 |
| Fukuyama, M | 1 |
| Kato, K | 1 |
| Itoh, H | 1 |
| Makiyama, T | 1 |
| Omatsu-Kanbe, M | 1 |
| Matsuura, H | 2 |
| Horie, M | 3 |
| Ohno, S | 2 |
| Smith, JL | 2 |
| Reloj, AR | 1 |
| Nataraj, PS | 2 |
| Bartos, DC | 2 |
| Schroder, EA | 1 |
| Moss, AJ | 1 |
| Anderson, CL | 3 |
| January, CT | 6 |
| Delisle, BP | 3 |
| Odening, KE | 2 |
| Jung, BA | 1 |
| Lang, CN | 1 |
| Cabrera Lozoya, R | 1 |
| Ziupa, D | 2 |
| Menza, M | 1 |
| Relan, J | 1 |
| Franke, G | 2 |
| Perez Feliz, S | 2 |
| Koren, G | 2 |
| Zehender, M | 2 |
| Bode, C | 2 |
| Brunner, M | 2 |
| Sermesant, M | 1 |
| Föll, D | 1 |
| Wang, WL | 1 |
| Zhang, SS | 1 |
| Deng, J | 1 |
| Zhao, JY | 1 |
| Zhao, CQ | 1 |
| Lin, L | 1 |
| Zhang, CT | 1 |
| Lv, JG | 1 |
| Beck, J | 1 |
| Hartmann, M | 1 |
| Hansen, RS | 1 |
| Olesen, SP | 1 |
| Rønn, LC | 1 |
| Grunnet, M | 1 |
| Sale, H | 1 |
| Wang, J | 1 |
| O'Hara, TJ | 1 |
| Tester, DJ | 1 |
| Phartiyal, P | 1 |
| He, JQ | 1 |
| Rudy, Y | 1 |
| Ackerman, MJ | 1 |
| Robertson, GA | 3 |
| Hardman, RM | 1 |
| Forsythe, ID | 1 |
| Schwoerer, AP | 1 |
| Kebernik, J | 1 |
| Ehmke, H | 1 |
| Friederich, P | 1 |
| Abi-Gerges, N | 1 |
| Holkham, H | 1 |
| Jones, EM | 1 |
| Pollard, CE | 1 |
| Valentin, JP | 1 |
| Wu, L | 2 |
| Ma, J | 1 |
| Li, H | 1 |
| Wang, C | 1 |
| Grandi, E | 1 |
| Zhang, P | 1 |
| Luo, A | 1 |
| Bers, DM | 1 |
| Shryock, JC | 2 |
| Belardinelli, L | 2 |
| Mihic, A | 1 |
| Chauhan, VS | 1 |
| Gao, X | 1 |
| Oudit, GY | 1 |
| Tsushima, RG | 1 |
| McBride, CM | 1 |
| Said, TH | 1 |
| Wilson, LD | 1 |
| Jeyaraj, D | 1 |
| Fossa, AA | 4 |
| Rosenbaum, DS | 1 |
| Danielsson, C | 1 |
| Brask, J | 1 |
| Sköld, AC | 1 |
| Genead, R | 1 |
| Andersson, A | 1 |
| Andersson, U | 1 |
| Stockling, K | 1 |
| Pehrson, R | 1 |
| Grinnemo, KH | 1 |
| Salari, S | 1 |
| Hellmold, H | 1 |
| Danielsson, B | 1 |
| Sylvén, C | 1 |
| Elinder, F | 1 |
| DePasquale, MJ | 1 |
| Raunig, DL | 2 |
| Avery, MJ | 1 |
| Leishman, DJ | 1 |
| Choi, BR | 1 |
| Burton, F | 1 |
| Salama, G | 1 |
| Yamauchi, S | 1 |
| Yamaki, M | 1 |
| Watanabe, T | 1 |
| Yuuki, K | 1 |
| Kubota, I | 1 |
| Tomoike, H | 1 |
| Strauss, HC | 1 |
| Rasmusson, RL | 1 |
| Ishii, K | 1 |
| Nagai, M | 1 |
| Takahashi, M | 1 |
| Endoh, M | 1 |
| Mizuno, H | 1 |
| Adachi, H | 1 |
| Kimura, J | 1 |
| Sawa, Y | 1 |
| Kakiki, M | 1 |
| Lansdell, K | 1 |
| Saito, M | 1 |
| Kerns, WD | 1 |
| Gong, Q | 3 |
| Zhou, Z | 4 |
| Song, Y | 1 |
| Wisialowski, T | 2 |
| Magnano, A | 1 |
| Wolfgang, E | 1 |
| Winslow, R | 1 |
| Gorczyca, W | 1 |
| Crimin, K | 2 |
| Aiba, T | 1 |
| Shimizu, W | 1 |
| Inagaki, M | 1 |
| Noda, T | 1 |
| Miyoshi, S | 1 |
| Zankov, DP | 1 |
| Toyoda, F | 1 |
| Sunagawa, K | 1 |
| Rossenbacker, T | 1 |
| Mubagwa, K | 1 |
| Jongbloed, RJ | 1 |
| Vereecke, J | 1 |
| Devriendt, K | 1 |
| Gewillig, M | 1 |
| Carmeliet, E | 1 |
| Collen, D | 1 |
| Heidbüchel, H | 1 |
| Carmeliet, P | 1 |
| Shiotani, M | 1 |
| Harada, T | 1 |
| Abe, J | 1 |
| Sawada, Y | 1 |
| Hashimoto, K | 1 |
| Hamada, Y | 1 |
| Horii, I | 1 |
| Jones, MA | 1 |
| Kamiya, K | 1 |
| Niwa, R | 1 |
| Mitcheson, JS | 1 |
| Sanguinetti, MC | 1 |
| Rajamani, S | 1 |
| Eckhardt, LL | 1 |
| Valdivia, CR | 1 |
| Klemens, CA | 1 |
| Gillman, BM | 1 |
| Holzem, KM | 1 |
| Anson, BD | 1 |
| Makielski, JC | 1 |
| Michael, G | 1 |
| Dempster, J | 1 |
| Kane, KA | 1 |
| Coker, SJ | 1 |
| Roy, J | 1 |
| Vantol, B | 1 |
| Cowley, EA | 1 |
| Blay, J | 1 |
| Linsdell, P | 1 |
| Okada, Y | 1 |
| Ogawa, S | 1 |
| Sadanaga, T | 1 |
| Mitamura, H | 1 |
| Merot, J | 1 |
| Riochet, D | 1 |
| Le Marec, H | 1 |
| Escande, D | 1 |
| Emmi, A | 1 |
| Wenzel, HJ | 1 |
| Schwartzkroin, PA | 1 |
| Taglialatela, M | 1 |
| Castaldo, P | 1 |
| Bianchi, L | 1 |
| Nerbonne, J | 1 |
| Janigro, D | 1 |
| Studenik, CR | 1 |
| Lengyel, C | 1 |
| Iost, N | 2 |
| Virág, L | 2 |
| Varró, A | 2 |
| Lathrop, DA | 1 |
| Papp, JG | 2 |
| Opincariu, M | 1 |
| Szolnoky, J | 1 |
| Szécsi, J | 1 |
| Bogáts, G | 1 |
| Szenohradszky, P | 1 |
| Ficker, E | 1 |
| Obejero-Paz, CA | 1 |
| Zhao, S | 1 |
| Brown, AM | 1 |
| Verheijck, EE | 1 |
| Wilders, R | 1 |
| Bouman, LN | 1 |
1 review available for e 4031 and Long QT Syndrome
| Article | Year |
|---|---|
HERG channel and cancer: A mechanistic review of carcinogenic processes and therapeutic potential.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Carcinogenesis; Cell Movement; Cell Proliferation; | 2020 |
1 trial available for e 4031 and Long QT Syndrome
| Article | Year |
|---|---|
Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour Holter electrocardiography.
Topics: Adult; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Electrocardiography, Ambulatory; Female; | 1996 |
45 other studies available for e 4031 and Long QT Syndrome
| Article | Year |
|---|---|
Identification of two nervous system-specific members of the erg potassium channel gene family.
Topics: Animals; Cation Transport Proteins; Cloning, Molecular; DNA-Binding Proteins; DNA, Complementary; El | 1997 |
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go- | 2002 |
Functional Impact of BeKm-1, a High-Affinity hERG Blocker, on Cardiomyocytes Derived from Human-Induced Pluripotent Stem Cells.
Topics: Action Potentials; Anti-Arrhythmia Agents; Calcium; Calcium Channels; Cell Differentiation; ERG1 Pot | 2020 |
Isogenic Sets of hiPSC-CMs Harboring Distinct KCNH2 Mutations Differ Functionally and in Susceptibility to Drug-Induced Arrhythmias.
Topics: Arrhythmias, Cardiac; Cell Line; Electrophysiology; ERG1 Potassium Channel; Gene Editing; Genetic Pr | 2020 |
Novel intracellular transport-refractory mutations in KCNH2 identified in patients with symptomatic long QT syndrome.
Topics: Adult; Animals; CHO Cells; Cricetinae; Cricetulus; ERG1 Potassium Channel; Female; Humans; Kv1.1 Pot | 2018 |
Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Endoplasmic Reticulum; ERG1 Potassium Channel; Ethe | 2013 |
Spatial correlation of action potential duration and diastolic dysfunction in transgenic and drug-induced LQT2 rabbits.
Topics: Action Potentials; Animals; Animals, Genetically Modified; Anti-Arrhythmia Agents; Arrhythmias, Card | 2013 |
KN-93, A CaMKII inhibitor, suppresses ventricular arrhythmia induced by LQT2 without decreasing TDR.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzylamines; Calcium-Calm | 2013 |
Pronounced effects of HERG-blockers E-4031 and erythromycin on APD, spatial APD dispersion and triangulation in transgenic long-QT type 1 rabbits.
Topics: Action Potentials; Animals; Animals, Genetically Modified; Erythromycin; Female; Heart; Long QT Synd | 2014 |
In vivo effects of the IKr agonist NS3623 on cardiac electrophysiology of the guinea pig.
Topics: Animals; Anti-Arrhythmia Agents; Consciousness; Delayed Rectifier Potassium Channels; Dose-Response | 2008 |
Physiological properties of hERG 1a/1b heteromeric currents and a hERG 1b-specific mutation associated with Long-QT syndrome.
Topics: Action Potentials; Amino Acid Substitution; Anti-Arrhythmia Agents; Cell Line; Ether-A-Go-Go Potassi | 2008 |
Ether-à-go-go-related gene K+ channels contribute to threshold excitability of mouse auditory brainstem neurons.
Topics: Action Potentials; Animals; Auditory Pathways; Brain Stem; ERG1 Potassium Channel; Ether-A-Go-Go Pot | 2009 |
The subtype-specific effects of droperidol on action potential duration in cellular and computational models of long QT syndrome.
Topics: Action Potentials; Adult; Animals; Anti-Arrhythmia Agents; Antiemetics; Cardioplegic Solutions; Cell | 2010 |
hERG subunit composition determines differential drug sensitivity.
Topics: Action Potentials; Arrhythmias, Cardiac; Cell Line, Transformed; Drug Evaluation, Preclinical; Ether | 2011 |
Late sodium current contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Bradycardia; Disease Models, Anima | 2011 |
Trafficking defect and proteasomal degradation contribute to the phenotype of a novel KCNH2 long QT syndrome mutation.
Topics: Adult; Blotting, Western; Cell Membrane; Electrophysiology; ERG1 Potassium Channel; Ether-A-Go-Go Po | 2011 |
Trafficking-deficient hERG K⁺ channels linked to long QT syndrome are regulated by a microtubule-dependent quality control compartment in the ER.
Topics: Anti-Arrhythmia Agents; Blotting, Western; Endoplasmic Reticulum; Ether-A-Go-Go Potassium Channels; | 2011 |
Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
Topics: Action Potentials; Animals; Bepridil; Dogs; Dose-Response Relationship, Drug; Electrocardiography; E | 2012 |
Exploration of human, rat, and rabbit embryonic cardiomyocytes suggests K-channel block as a common teratogenic mechanism.
Topics: Action Potentials; Animals; Atrioventricular Block; Cells, Cultured; Electrocardiography; ERG1 Potas | 2013 |
The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment.
Topics: Animals; Anti-Arrhythmia Agents; Butylamines; Cisapride; Disease Models, Animal; Dogs; Female; Heart | 2002 |
Cytosolic Ca2+ triggers early afterdepolarizations and Torsade de Pointes in rabbit hearts with type 2 long QT syndrome.
Topics: Animals; Anti-Arrhythmia Agents; Artifacts; Calcium; Calcium Signaling; Cryosurgery; Cytosol; Female | 2002 |
Restitution properties and occurrence of ventricular arrhythmia in LQT2 type of long QT syndrome.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Disease Models, Animal; Disease Suscept | 2002 |
Restitution, ventricular fibrillation, and drugs: where are we now?
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrophysiologic Techniques, Cardiac; | 2002 |
Dissociation of E-4031 from the HERG channel caused by mutations of an amino acid results in greater block at high stimulation frequency.
Topics: Animals; Anti-Arrhythmia Agents; Cation Transport Proteins; Dose-Response Relationship, Drug; Ether- | 2003 |
Cardiovascular assessment of ER-118585, a selective phosphodiesterase 5 inhibitor.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Action Potentials; Animals; Cardiac Pacing, Artificial; Cardiov | 2003 |
Pharmacological rescue of trafficking defective HERG channels formed by coassembly of wild-type and long QT mutant N470D subunits.
Topics: Cation Transport Proteins; Cell Line; Cell Membrane; Endoplasmic Reticulum; Ether-A-Go-Go Potassium | 2004 |
Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes.
Topics: Acetanilides; Action Potentials; Animals; Chromans; Cnidarian Venoms; Delayed Rectifier Potassium Ch | 2004 |
Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition.
Topics: Adrenergic beta-Agonists; Animals; Bradycardia; Dogs; ERG1 Potassium Channel; Ether-A-Go-Go Potassiu | 2005 |
Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cats; Chromans; Heart; | 2005 |
Novel mutation in the Per-Arnt-Sim domain of KCNH2 causes a malignant form of long-QT syndrome.
Topics: Adult; Blotting, Western; Cell Line; Death, Sudden, Cardiac; Electrophysiology; ERG1 Potassium Chann | 2005 |
Practical application of guinea pig telemetry system for QT evaluation.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Bepridil; Cisapride; Disease Models, Animal; | 2005 |
QT prolongation modifies dynamic restitution and hysteresis of the beat-to-beat QT-TQ interval relationship during normal sinus rhythm under varying states of repolarization.
Topics: Acetamides; Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzodiazepino | 2006 |
Mechanisms of pharmacological rescue of trafficking-defective hERG mutant channels in human long QT syndrome.
Topics: Calnexin; Detergents; Endoplasmic Reticulum; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channel | 2006 |
Molecular determinants of HERG channel block.
Topics: DNA Primers; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Kinetics; Long QT Syn | 2006 |
Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Blotting, Western; Cell Line; Cell Membrane; Cisapr | 2006 |
Potentiation of E-4031-induced torsade de pointes by HMR1556 or ATX-II is not predicted by action potential short-term variability or triangulation.
Topics: Action Potentials; Animals; Chromans; Cnidarian Venoms; Delayed Rectifier Potassium Channels; Dose-R | 2007 |
Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carcinoma cell line MCF-7.
Topics: Adenocarcinoma; Anti-Allergic Agents; Anti-Arrhythmia Agents; Astemizole; Breast Neoplasms; Cell Pro | 2008 |
Adult KCNE1-knockout mice exhibit a mild cardiac cellular phenotype.
Topics: Action Potentials; Animals; Chromans; Electric Conductivity; Electrophysiology; Heart; Homozygote; I | 1998 |
Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects.
Topics: Anti-Arrhythmia Agents; Astemizole; Biological Transport; Cation Transport Proteins; Cell Compartmen | 1999 |
Do glia have heart? Expression and functional role for ether-a-go-go currents in hippocampal astrocytes.
Topics: Animals; Anti-Arrhythmia Agents; Astrocytes; Cation Transport Proteins; Cell Communication; Cesium; | 2000 |
Differences in action potential and early afterdepolarization properties in LQT2 and LQT3 models of long QT syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cell Separation; Electric Stimulation; Electroph | 2001 |
Pharmacological block of the slow component of the outward delayed rectifier current (I(Ks)) fails to lengthen rabbit ventricular muscle QT(c) and action potential duration.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Benzodiazepines; Cell Separation; Chromans; Colf | 2001 |
The slow component of the delayed rectifier potassium current in undiseased human ventricular myocytes.
Topics: Adult; Benzodiazepines; Calcium Channel Blockers; Cell Separation; Chromans; Colforsin; Female; Huma | 2001 |
The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations.
Topics: Anti-Arrhythmia Agents; Astemizole; Benzimidazoles; Binding Sites; Blotting, Western; Cation Transpo | 2002 |
Atrio-sinus interaction demonstrated by blockade of the rapid delayed rectifier current.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Biological Clocks; Cation Transport Proteins; Co | 2002 |